M&A / Deals

Cancer biotech Parabilis books record IPO, raising $670m

Pharmaphorum

Parabilis has broken the IPO record set by Kailera in April, packing its coffers as it starts an ambitious trial programme for lead drug zolucatetide.

Oncology

Read full story

pharminent June 10, 2026 (Last updated: June 10, 2026)

Pharmaphorum

Parabilis has broken the IPO record set by Kailera in April, packing its coffers as it starts an ambitious trial programme for lead drug zolucatetide.

Oncology

Read full story

Related Stories

AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine

Aditxt and Ignite announce merger plans with strategic partner

Alzecure enters collaboration and with Lilly for Alzheimer’s project

You May Have Missed

Aquipta recommended by NICE for acute migraine treatment

AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine

Lilly wins new FDA approval for eczema drug Ebglyss

Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug